ATYR1923 PULMONARY SARCOIDOSIS MULTIPLE ASCENDING DOSE TRIAL: PHASE 1b/2a

In the fourth quarter of 2018, we initiated a Phase 1b/2a study evaluating our lead candidate, ATYR1923, in patients with pulmonary sarcoidosis.

This Phase 1b/2a study is a multiple-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate safety, tolerability and immunogenicity of multiple doses of ATYR1923, as well as to evaluate established clinical endpoints and potential biomarkers to assess preliminary efficacy.

© 2007 - 2019   aTyr Pharma.   Legal   Privacy Policy